BiotechFinances
The essentials of the week of May 11 to 15, 2026
ESSENTIAL

The essentials of the week of May 11 to 15, 2026

May 14, 2026

A focused selection of the signals that matter in biotech, medtech and healthtech: financings, deals, clinical data and strategic moves of the week.

Translated by artificial intelligence from the original French version. Learn more

WORLD

(United States/Medtech/Urology) - Rivermark Medical closes a $20M Series D led by Andera Partners, with support from existing investors and a strategic investor (undisclosed), to accelerate development of its FloStent system for benign prostatic hyperplasia (BPH). The funds will finance the pivotal RAPID III trial, U.S. regulatory approval and preparation for commercial launch of this first‑line, non‑surgical, reversible, outpatient‑implantable therapy performed dur...

Written byRédaction BTFBiotechFinances

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.

Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.

Subscribe

Read more...

This is a standard plan article, subscribe to access the full content